PE133699A1 - Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica - Google Patents

Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica

Info

Publication number
PE133699A1
PE133699A1 PE1998001146A PE00114698A PE133699A1 PE 133699 A1 PE133699 A1 PE 133699A1 PE 1998001146 A PE1998001146 A PE 1998001146A PE 00114698 A PE00114698 A PE 00114698A PE 133699 A1 PE133699 A1 PE 133699A1
Authority
PE
Peru
Prior art keywords
antiviral
methyl
cyan
halo
benzimidazole
Prior art date
Application number
PE1998001146A
Other languages
English (en)
Spanish (es)
Inventor
Nick Nikolaides
Michael Gazda
Sophie Lee Bogdan
Iii Charles Andrew Cruze
Thomas Lee Cupps
Roy Lee Dobson
Sheri Ann Gilbert
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE133699A1 publication Critical patent/PE133699A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE1998001146A 1997-11-24 1998-11-25 Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica PE133699A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US6670097P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
PE133699A1 true PE133699A1 (es) 2000-03-05

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001146A PE133699A1 (es) 1997-11-24 1998-11-25 Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica

Country Status (23)

Country Link
US (1) US6486190B1 (https=)
EP (1) EP1037887B1 (https=)
JP (1) JP2001524478A (https=)
KR (1) KR20010032435A (https=)
CN (1) CN1284073A (https=)
AT (1) ATE271048T1 (https=)
BR (1) BR9815017A (https=)
CA (1) CA2311344C (https=)
CO (1) CO4970802A1 (https=)
DE (1) DE69825075T2 (https=)
ES (1) ES2223143T3 (https=)
HU (1) HUP0101469A3 (https=)
IL (1) IL136303A (https=)
IN (1) IN190809B (https=)
NO (1) NO20002655L (https=)
NZ (1) NZ504707A (https=)
PE (1) PE133699A1 (https=)
PL (1) PL340711A1 (https=)
RU (1) RU2193562C2 (https=)
SK (1) SK7792000A3 (https=)
TR (1) TR200002242T2 (https=)
TW (1) TW505642B (https=)
WO (1) WO1999026942A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
RU2225401C1 (ru) * 2002-09-16 2004-03-10 Катаев Валерий Алексеевич 5(6)-нитро-1-(1,1-диоксотиетанил-3)-2-хлорбензимидазол, проявляющий биологическую активность
US20040167194A1 (en) 2003-02-20 2004-08-26 Randall Jared Lynn Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form
CN100366603C (zh) * 2003-02-20 2008-02-06 隆萨股份公司 N-取代甲酰胺的制备方法
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PT1761266E (pt) * 2004-05-25 2013-06-04 Galderma Pharma Sa Compostos, formulações, e métodos para tratamento ou prevenção de distúrbios inflamatórios da pele
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
RU2306137C1 (ru) * 2005-12-28 2007-09-20 Денис Вячеславович Лисицын Средство для профилактики и лечения гриппа
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
WO2015073736A1 (en) * 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Methods and compositions for treating adhd
CA3006563A1 (en) * 2015-11-30 2017-06-08 Novus Therapeutics, Inc. Compositions and methods for otologic prophylaxis and treatment
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0025269B1 (en) 1979-08-23 1985-11-13 Beecham Group Plc Anti-diarrhoea veterinary composition
WO1982000824A1 (en) 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
TW300219B (https=) * 1991-09-14 1997-03-11 Hoechst Ag
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CA2196792A1 (en) 1994-08-04 1996-02-15 Yoon T. Jeon Novel benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor

Also Published As

Publication number Publication date
NZ504707A (en) 2002-11-26
HUP0101469A2 (hu) 2001-10-28
CA2311344C (en) 2006-02-07
WO1999026942A1 (en) 1999-06-03
BR9815017A (pt) 2001-09-11
IL136303A0 (en) 2001-05-20
EP1037887B1 (en) 2004-07-14
US6486190B1 (en) 2002-11-26
CA2311344A1 (en) 1999-06-03
NO20002655D0 (no) 2000-05-24
TW505642B (en) 2002-10-11
TR200002242T2 (tr) 2000-11-21
ES2223143T3 (es) 2005-02-16
EP1037887A1 (en) 2000-09-27
HUP0101469A3 (en) 2003-01-28
NO20002655L (no) 2000-07-24
DE69825075D1 (de) 2004-08-19
WO1999026942A8 (en) 2000-08-03
CN1284073A (zh) 2001-02-14
CO4970802A1 (es) 2000-11-07
DE69825075T2 (de) 2005-08-25
IN190809B (https=) 2003-08-23
KR20010032435A (ko) 2001-04-25
ATE271048T1 (de) 2004-07-15
JP2001524478A (ja) 2001-12-04
IL136303A (en) 2004-02-08
RU2193562C2 (ru) 2002-11-27
SK7792000A3 (en) 2001-01-18
PL340711A1 (en) 2001-02-26

Similar Documents

Publication Publication Date Title
PE133699A1 (es) Compuestos de benzimidazol 5-sustituido con mayor estabilidad metabolica
BR9408343A (pt) Derivados 5-(2-imidazolinil amino) benzimidazol sua preparação e seu uso como agonistas alfa-2 adrenoceptor
PE20010039A1 (es) Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato
PE20050145A1 (es) Dihidroquinazolinas sustituidas como agentes antivirales
DK1654002T4 (da) Sammensætninger til fremføring af terapeutiske midler til øjnene
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
AR017122A1 (es) DERIVADOS DE BENZAMIDOXIMA, BENZONITRILOS Y COMPUESTOS DE BENZAMIDOXIMAS INTERMEDIARIOS EN LA SíNTESIS DE DICHOS DERIVADOS, LA UTILIZACIoN DE LOS MISMOS PARA CONTROLAR HONGOS DANINOS, LAS COMPOSICIONES FUNGUICIDAS QUE LOS CONTIENEN Y EL MÉTODO PARA CONTROLAR HONGOS DANINOS CON DICHOS DERIVADOS O SUS
PE20091689A1 (es) DERIVADOS DE 4-AMINOCICLOHEXANO SUSTITUIDO CON ACTIVIDAD SOBRE RECEPTORES µ Y ORL-1
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20040608A1 (es) Compuestos de alquino con efecto antagonico de la hcm y medicamentos que los contienen
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
DK0775129T3 (da) 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
DE69326610D1 (de) Arzneimittel gegen glaukom
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR058719A1 (es) Derivados de isoxazol-4-il-oxadiazol
PE20140968A1 (es) Derivados de benzamida sustituida
PE16399A1 (es) Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores
PE38095A1 (es) Compuesto 7-(2-imidazolinilamino) quinolina util como agonista de adrenoreceptor alfa-2
AR012426A1 (es) Un compuesto de indazol amida, un procedimiento para prepararlo, compuestos intermediarios, y una composicion farmaceutica que comprende dicho compuesto de indazol amida.
PE20080840A1 (es) Metodos para administrar agentes hipoglucemiantes de larga duracion
PE20080378A1 (es) Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa
PE20040682A1 (es) Derivados de ciclobutano como antagonistas de nk1
AR058271A1 (es) Compuesto herbicida a base de fenoxaprop.
PE20050350A1 (es) 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobencenos sustituidos como agonistas de 5-ht1f

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed